Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ILK | Q13418 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952192 | 0.89 | TNK2 (0.47) | TNK2SRCMAPK1MAPTFLT3 | |
| SCHEMBL2959696 | 0.86 | TNK2 (0.58) | TNK2SRCKDM4ECYP3A4KDR | |
| SCHEMBL2955937 | 0.86 | SRC (0.52) | TNK2SRCMAPTCYP3A4HPGD | |
| SCHEMBL2953623 | 0.86 | TNK2 (0.57) | TNK2SRCKDM4ECYP3A4KDR | |
| SCHEMBL2955951 | 0.81 | TNK2 (0.42) | TNK2SRCIGF1RCA12CA2 | |
| SCHEMBL2957977 | 0.77 | TNK2 (0.46) | TNK2SRCKDRFLT3IGF1R | |
| SCHEMBL4701225 | 0.77 | TNK2 (0.49) | TNK2MEN1KMT2ARAB9ASRC | |
| SCHEMBL2949189 | 0.76 | TNK2 (0.46) | TNK2SRC | |
| SCHEMBL30338760 | 0.74 | TNK2 (1.00) | TNK2KDR | |
| SCHEMBL2952193 | 0.72 | TNK2 (0.64) | TNK2KDRWEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763624-B2 | Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors | AMGEN INC. (US) | 2010-07-27 | — | — | US | claimed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | claimed |
| US-7763624-B2 | Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors | AMGEN INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | LCK, MAP4K5, TPMT | TNK2 113/4885MEN1 1368/4885KMT2A 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.